DPDaily Peptide

KPV · DECODED

← Back to Decoded
GREY MARKETANTI-INFLAMMATORY · α-MSH FRAGMENT

KPV

Decoded · Grey Market · Anti-Inflammatory Research Peptide

Three amino acids from one of the body's own anti-inflammatory hormones. KPV is the last three amino acids of alpha-melanocyte stimulating hormone (alpha-MSH): lysine, proline, and valine. It carries the anti-inflammatory properties of the parent hormone without the tanning and pigmentation effects. That is a logical pharmacological concept. The clinical evidence in humans has not followed yet.

BY THE NUMBERS

3
AMINO ACIDS · LYS-PRO-VAL · C-TERMINAL FRAGMENT OF α-MSH
0
REGISTERED COMPLETED HUMAN CLINICAL TRIALS
0
FDA APPROVALS OR ACTIVE INDs
2026
PCAC MEETING #1 SCHEDULED JULY 23–24 FOR 503A REVIEW

HOW IT WORKS

A C-terminal tripeptide fragment of alpha-MSH. Binds melanocortin receptors (primarily MC1R and MC3R) and activates downstream anti-inflammatory signaling, suppressing NF-kB activation and reducing pro-inflammatory cytokines. All human-relevant mechanistic evidence is from in vitro and animal models. No human pharmacokinetic data exists.

WHERE IT CAME FROM

KPV is a tripeptide comprising the terminal three amino acids of alpha-melanocyte stimulating hormone (α-MSH): lysine (K), proline (P), and valine (V). Alpha-MSH is a 13-amino acid peptide produced in the pituitary and skin that regulates pigmentation through MC1R and also exerts anti-inflammatory effects through multiple melanocortin receptors. Researchers investigating α-MSH's anti-inflammatory properties identified the C-terminal tripeptide KPV as the fragment responsible for a significant portion of those effects, and found that it retained anti-inflammatory activity while lacking the melanocortin receptor activity responsible for tanning and pigmentation effects.

The proposed mechanism is inhibition of NF-κB signaling, a central pathway in immune activation and inflammatory cytokine production. NF-κB inhibitors as a class are an active area of pharmaceutical research, and the concept that a short endogenous peptide fragment could modulate this pathway without the broader hormonal effects of full α-MSH is pharmacologically interesting. The evidence base, however, remains almost entirely preclinical. KPV's reputation in the grey market is largely built on its mechanism and the biological plausibility of the α-MSH connection, not on human trial data.

THE STUDIES

Preclinical
Anti-inflammatory animal models: Preclinical research has shown KPV reduces inflammatory cytokine production in cell culture and animal models of inflammatory bowel disease, skin inflammation, and other inflammatory conditions. NF-κB inhibition has been demonstrated in vitro. Mouse models of colitis and skin inflammation showed reduced inflammatory markers following KPV administration. These results are mechanistically consistent and provide the rationale for human investigation.
Preclinical
Gut barrier protection studies: A subset of preclinical research has examined KPV's effects on intestinal epithelial barrier integrity, which is relevant to conditions like Crohn's disease and ulcerative colitis. Cell culture and mouse model data suggest KPV can reduce inflammatory damage to the gut lining. This is an active area of preclinical interest. No human interventional trials have tested this application.
None
Human clinical trials: There are no registered completed human clinical trials for KPV for any indication. No IND is on file with the FDA for KPV. The compound's entire clinical reputation is built on preclinical mechanism data and observational reports from grey market users. This is a significant gap for a compound that people are self-administering for conditions like inflammatory bowel disease, where the stakes of an ineffective or harmful intervention are high.

WHAT THE STUDIES SHOW

PRECLINICAL DATA

  • ▸NF-κB inhibition in cell culture models
  • ▸Anti-inflammatory cytokine reduction in animal models
  • ▸Gut lining protection signals in colitis mouse models
  • ▸Skin inflammation reduction in animal studies

MECHANISTIC RATIONALE

  • ▸Derived from endogenous anti-inflammatory hormone (α-MSH)
  • ▸C-terminal fragment carries anti-inflammatory activity without pigmentation effects
  • ▸Short tripeptide structure is relatively stable
  • ▸NF-κB pathway is a validated anti-inflammatory target

UNKNOWN (HUMAN)

  • ▸Whether anti-inflammatory effects translate to humans
  • ▸Effective dose, route, and frequency in humans
  • ▸Safety profile at grey market doses
  • ▸Comparative effectiveness vs. approved anti-inflammatory therapies

SIDE EFFECTS

REPORTED (ANECDOTAL)

  • ▸Injection site reactions
  • ▸Few adverse events reported in grey market use
  • ▸No controlled safety data exists

NOTABLE / MONITOR FOR

  • ▸Grey market supply: purity, sterility, and concentration unverified
  • ▸NF-κB suppression: theoretical concern with long-term or high-dose immune suppression
  • ▸No long-term safety data from controlled studies
  • ▸Self-administration for inflammatory GI disease without physician involvement carries meaningful risk

REGULATORY STATUS

FDA STATUS
Not approved · Category 2 removal pending PCAC review
PHASE
No clinical trials · Preclinical only
PROJECTED NDA
None · No pharmaceutical development program

KPV was on the FDA's Category 2 list, explicitly prohibiting it from 503A compounding. On April 15, 2026, the FDA removed KPV from that prohibition as part of a 12-compound review. This does not mean KPV is approved or compoundable. The PCAC is scheduled to review KPV and six other compounds at the July 23–24, 2026 meeting to assess whether 503A compounding eligibility is appropriate. There is no active pharmaceutical development program pursuing FDA approval for KPV. It is not on any approved bulk drug substances list. Anyone obtaining it is doing so through unregulated channels.

PROS & CONS

PROS

  • +Mechanistically derived from an endogenous anti-inflammatory hormone (α-MSH)
  • +NF-κB inhibition is a well-validated anti-inflammatory target
  • +Short tripeptide structure: relatively low molecular weight and potentially good stability
  • +Lacks pigmentation side effects of the parent molecule (no MC1R activity)
  • +PCAC review in July 2026 may clarify regulatory path

CONS

  • −Zero completed human interventional trials
  • −No FDA approval, no IND on file
  • −Grey market supply: purity, sterility, and concentration unverified
  • −No established dosing protocol based on human data
  • −Approved anti-inflammatory therapies exist for most target indications
  • −Risk of unverified use for serious inflammatory conditions without physician oversight

DAILY PEPTIDE VERDICT

RANKING

Mechanistically Rational, Evidentially Missing

KPV has a compelling pharmacological concept behind it: isolate the anti-inflammatory portion of a hormone the body already makes, remove the parts that cause pigmentation effects, and use the result for inflammatory conditions. That logic makes sense. The problem is that a logical concept is not the same as clinical evidence. KPV has no completed human trials for any indication. The gap between preclinical data and clinical proof is significant, and the conditions where KPV is most commonly self-administered — inflammatory bowel disease, skin conditions — have established approved treatments with Phase 3 data behind them.

Also in IMMUNE

// IMMUNE

Thymosin α-1

GREY MARKETPHASE 3+

Not FDA approved · Internationally approved as Zadaxin in 35+ countries

// IMMUNE

LL-37

GREY MARKETPHASE 1

DISCLAIMER · EDUCATIONAL USE ONLY

This document is for educational and informational purposes only. KPV does not hold general FDA approval for human use. Information here synthesizes publicly available research data and does not constitute medical advice.